SMILE

Kao Rated Triple-A for Climate Change, Water Security, and Forests for Fourth Consecutive Year by CDP

Retrieved on: 
Tuesday, February 6, 2024

Kao, a leading manufacturer of personal care, household, and cosmetics products, received the highest triple-A score for its sustainability initiatives involving climate change, forests, and water security.

Key Points: 
  • Kao, a leading manufacturer of personal care, household, and cosmetics products, received the highest triple-A score for its sustainability initiatives involving climate change, forests, and water security.
  • More than 21,000 firms were evaluated for the ‘A List’, with only 10 selected for inclusion across the three categories.
  • Kao has now been included in the Climate Change ‘A List’ for the fifth time, the Forests ‘A List’ for the fourth time, and the Water Security ‘A List’ for the seventh time.
  • In the forests area, Kao has created a “Palm Oil Dashboard” on its website, which provides information on its palm oil procurement activities.

NVISION Continues Expansion in Texas with Parkhurst NuVision Joint Venture

Retrieved on: 
Thursday, January 18, 2024

NVISION Eye Centers, a national leader in eye care services, is proud to announce its continued expansion in Texas with a new Joint Venture partnership with Parkhurst NuVision in San Antonio and New Braunfels.

Key Points: 
  • NVISION Eye Centers, a national leader in eye care services, is proud to announce its continued expansion in Texas with a new Joint Venture partnership with Parkhurst NuVision in San Antonio and New Braunfels.
  • Parkhurst NuVision (PNV) was founded in 2013 by Dr. Gregory Parkhurst.
  • NVision’s unique Joint Venture model is very different from private equity funds because at its core lies physician leadership along with substantial equity and influence.
  • “We are thrilled to partner with Dr. Parkhurst and the Parkhurst NuVision team,” said Chris Karkenny, CEO of NVISION.

EQS-News: U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Retrieved on: 
Saturday, January 13, 2024

The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.

Key Points: 
  • The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.
  • ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
  • With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
  • For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .

U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Retrieved on: 
Thursday, January 11, 2024

DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the U.S. market at a time when more than 8 million eyes have been treated with SMILE worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia and Europe.

Key Points: 
  • DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
  • The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.
  • With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
  • For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .

U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Retrieved on: 
Thursday, January 11, 2024

DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the U.S. market at a time when more than 8 million eyes have been treated with SMILE worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia and Europe.

Key Points: 
  • DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
  • The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.
  • With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
  • For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .

GOPIVOT™ CELEBRATES RENEWED PARTNERSHIP WITH C.A. SHORT COMPANY AND EMPHASIZES A FRESH FOCUS ON MENTAL HEALTH INITIATIVES IN 2024

Retrieved on: 
Monday, December 4, 2023

GoPivot is putting a strategic focus on mental health in 2024.

Key Points: 
  • GoPivot is putting a strategic focus on mental health in 2024.
  • Mental Health Focus in 2024:
    GoPivot is putting a strategic focus on mental health in 2024.
  • SMILE delves into crucial aspects of overall well-being, including Emotional Health, Relational Health, Occupational Health, Experiential Health, and Sleep.
  • These initiatives contribute to creating a workplace environment that encourages open dialogue, reduces stigma, and actively supports mental health.

National Down Syndrome Society Announces New Board Members and Executive Committee

Retrieved on: 
Tuesday, October 24, 2023

Washington D.C., Oct. 24, 2023 (GLOBE NEWSWIRE) -- At its Annual Meeting on September 24, the National Down Syndrome Society (NDSS) elected seven new members to its Board of Directors.

Key Points: 
  • Washington D.C., Oct. 24, 2023 (GLOBE NEWSWIRE) -- At its Annual Meeting on September 24, the National Down Syndrome Society (NDSS) elected seven new members to its Board of Directors.
  • He worked as an executive with JP Morgan Chase for more than 22 years and has a brother, Joe, who is 60 years old and has Down syndrome.
  • “NDSS has built a legacy of doing tremendous work for individuals with Down syndrome like my brother Joe.
  • With the new additions, the NDSS Board has expanded its geographic reach with board members from 14 states who bring a wide range of professional skills and personal experiences.

ZEISS advances cataract and corneal refractive surgical care with new workflow innovations

Retrieved on: 
Thursday, August 31, 2023

JENA, Germany and DUBLIN, Calif., Aug. 31, 2023 /PRNewswire/ -- ZEISS Medical Technology will showcase new ophthalmic innovations within the cataract and corneal refractive workflows at the European Society of Cataract and Refractive Surgery (ESCRS) annual conference from Sept. 8-12, 2023, in Vienna, Austria. As part of the ZEISS Medical Ecosystem, the following enhancements bolster ZEISS's leadership position in ophthalmic diagnostic and surgical workflow solutions, continuing the company's transformative progress toward more fully integrated, data-driven healthcare:

Key Points: 
  • - New ZEISS ATLAS 500 combines corneal topography and dry eye assessment for improved decision making within the cataract and corneal refractive workflows.
  • "As we continue to extend our position in digital ophthalmic solutions, ZEISS is proud to unveil our latest workflow innovations that are helping to transform the way surgical care is practiced today.
  • Within the ZEISS Premium Cataract Workflow, cataract surgeons are now offered new cutting-edge technology to boost both clinical and commercial success.
  • The new ZEISS ATLAS 500 integrates into both the ZEISS corneal refractive and cataract workflows.

ZEISS advances cataract and corneal refractive surgical care with new workflow innovations

Retrieved on: 
Thursday, August 31, 2023

JENA, Germany and DUBLIN, Calif., Aug. 31, 2023 /PRNewswire/ -- ZEISS Medical Technology will showcase new ophthalmic innovations within the cataract and corneal refractive workflows at the European Society of Cataract and Refractive Surgery (ESCRS) annual conference from Sept. 8-12, 2023, in Vienna, Austria. As part of the ZEISS Medical Ecosystem, the following enhancements bolster ZEISS's leadership position in ophthalmic diagnostic and surgical workflow solutions, continuing the company's transformative progress toward more fully integrated, data-driven healthcare:

Key Points: 
  • - New ZEISS ATLAS 500 combines corneal topography and dry eye assessment for improved decision making within the cataract and corneal refractive workflows.
  • "As we continue to extend our position in digital ophthalmic solutions, ZEISS is proud to unveil our latest workflow innovations that are helping to transform the way surgical care is practiced today.
  • Within the ZEISS Premium Cataract Workflow, cataract surgeons are now offered new cutting-edge technology to boost both clinical and commercial success.
  • The new ZEISS ATLAS 500 integrates into both the ZEISS corneal refractive and cataract workflows.

Promethean Showcases Its Newest ActivPanel and Google EDLA-Certified Android Device at This Year's ISTE Conference

Retrieved on: 
Monday, June 26, 2023

PHILADELPHIA, June 26, 2023 /PRNewswire/ -- Promethean, a leading global education technology company, is exhibiting its newly released OPS-A computing module and ActivPanel LX at the ISTELive 23 conference, taking place June 25-28 in Philadelphia. OPS-A, one of the first Google EDLA-certified devices designed for use with an interactive display, was built specifically to be paired with the ActivPanel LX, Promethean's new panel providing exceptional ease of use, flexibility, quality, and longevity.

Key Points: 
  • As a Google EDLA-certified Android device, the OPS-A allows users of the ActivPanel LX to access the Google Play Store right from their panel.
  • Many of the most popular Google apps are preloaded onto the device, including YouTube, Google Chrome, and Google Meet.
  • Having Google Drive on the panel also makes it easy to store content in the cloud, synchronize across devices, and share files.
  • Released earlier this year, the ActivPanel LX was created to meet the needs of an evolving interactive flat panel display market.